Cargando…
Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology
BACKGROUND: There is urgent need for new medications for psychiatric disorders. Mental illness is expected to become the leading cause of disability worldwide by 2030. Yet, the last two decades have seen the pharmaceutical industry withdraw from psychiatric drug discovery after costly late-stage tri...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7945970/ https://www.ncbi.nlm.nih.gov/pubmed/33694032 http://dx.doi.org/10.1007/s00213-021-05787-x |